Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients

Skinmed. 2019 May 29;17(2):107-109. eCollection 2019.

Aditya K Gupta^{1

2}, Robin P Love², William Abramovits^{3

4

5

6}, Kimberly D Vincent⁷

¹ Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada; agupta@execulink.com.
² Mediprobe Research Inc., London, Ontario, Canada.
³ Department of Medicine, Baylor University Medical Center, Dallas, TX.
⁴ Department of Dermatology, Dallas, TX.
⁵ Department of Family Practice, Dallas, TX.
⁶ University of Texas Southwestern Medical School,and Dermatology Treatment and Research Center, Dallas, TX.
⁷ Belle Meade Dermatology, Nashville, TN.

No abstract available

MeSH terms